Watson Gabrielle M, Gunzburg Menachem J, Ambaye Nigus D, Lucas William A H, Traore Daouda A, Kulkarni Ketav, Cergol Katie M, Payne Richard J, Panjikar Santosh, Pero Stephanie C, Perlmutter Patrick, Wilce Matthew C J, Wilce Jacqueline A
School of Chemistry, The University of Sydney , Sydney, New South Wales 2006, Australia.
Australian Synchrotron , 800 Blackburn Road, Clayton, Victoria 3168, Australia.
J Med Chem. 2015 Oct 8;58(19):7707-18. doi: 10.1021/acs.jmedchem.5b00609. Epub 2015 Sep 23.
The Grb7 adaptor protein is a therapeutic target for both TNBC and HER2+ breast cancer. A nonphosphorylated cyclic peptide 1 (known as G7-18NATE) inhibits Grb7 via targeting the Grb7-SH2 domain, but requires the presence of phosphate ions for both affinity and specificity. Here we report the discovery of malonate bound in the phosphotyrosine binding pocket of the apo-Grb7-SH2 structure. Based on this, we carried out the rational design and synthesis of two analogues of peptide 1 that incorporate carboxymethylphenylalanine (cmF) and carboxyphenylalanine (cF) as mimics of phosphotyrosine (pY). Binding studies using SPR confirmed that affinity for Grb7-SH2 domain is improved up to 9-fold over peptide 1 under physiological phosphate conditions (KD = 2.1-5.7 μM) and that binding is specific for Grb7-SH2 over closely related domains (low or no detectable binding to Grb2-SH2 and Grb10-SH2). X-ray crystallographic structural analysis of the analogue bearing a cmF moiety in complex with Grb7-SH2 has identified the precise contacts conferred by the pY mimic that underpin this improved molecular interaction. Together this study identifies and characterizes the tightest specific inhibitor of Grb7 to date, representing a significant development toward a new Grb7-targeted therapeutic.
Grb7衔接蛋白是三阴性乳腺癌(TNBC)和人表皮生长因子受体2阳性(HER2+)乳腺癌的治疗靶点。一种非磷酸化环肽1(称为G7-18NATE)通过靶向Grb7的SH2结构域来抑制Grb7,但亲和力和特异性都需要磷酸根离子的存在。在此,我们报告在无配体的Grb7-SH2结构的磷酸酪氨酸结合口袋中发现了丙二酸。基于此,我们对肽1的两种类似物进行了合理设计与合成,它们引入了羧甲基苯丙氨酸(cmF)和羧基苯丙氨酸(cF)作为磷酸酪氨酸(pY)的模拟物。使用表面等离子体共振(SPR)进行的结合研究证实,在生理磷酸盐条件下(解离常数KD = 2.1 - 5.7 μM),对Grb7-SH2结构域的亲和力比肽1提高了9倍,并且这种结合对Grb7-SH2结构域具有特异性,与密切相关的结构域相比(与Grb2-SH2和Grb10-SH2的结合很低或检测不到)。对与Grb7-SH2形成复合物的带有cmF部分的类似物进行的X射线晶体学结构分析,确定了由pY模拟物赋予的精确相互作用,这些相互作用支撑了这种改善的分子相互作用。这项研究共同鉴定并表征了迄今为止最紧密的Grb7特异性抑制剂,代表了针对Grb7的新型治疗方法的重大进展。